BrainsWay Ltd.

BrainsWay Ltd. is a global medical technology company specializing in advanced noninvasive neurostimulation treatments for mental health disorders. The company's mission is to boldly advance neuroscience to improve health and transform lives, aiming to make mental health accessible to all. BrainsWay maintains dual headquarters in Jerusalem, Israel, and Burlington, Massachusetts, USA.

The core of BrainsWay's offerings is its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, which utilizes patented H-Coils to stimulate deeper and broader areas of the brain. This technology is FDA-cleared for the treatment of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction. Additionally, Deep TMS is cleared for anxious depression, late-life depression, and for adolescents aged 15-21 with MDD. The company is actively conducting clinical trials to expand its applications across various psychiatric, neurological, and addiction disorders.

Under the leadership of CEO Hadar Levy, BrainsWay reported strong financial results for Q4 and full-year 2025, demonstrating significant revenue growth and increased profitability. Recent strategic developments include additional investments in Neurolief Ltd. and BrainStim Health Inc. in early 2026. The company also unveiled landmark data for its SWIFT™ Deep TMS protocol, an accelerated depression treatment that significantly reduces treatment time while maintaining efficacy. As of Q4 2025, BrainsWay's installed base comprised approximately 1,700 Deep TMS systems, solidifying its position as a leader in noninvasive neurostimulation with multiple FDA-cleared indications.